Global Chronic Myelogenous Leukemia Treatment Market to Reach $9 Billion by 2030
The global market for Chronic Myelogenous Leukemia Treatment estimated at US$6 Billion in the year 2022, is projected to reach a revised size of US$9 Billion by 2030, growing at a CAGR of 5.4% over the analysis period 2022-2030. Disease Specific Treatment, one of the segments analyzed in the report, is projected to record 6% CAGR and reach US$3.1 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Symptomatic Treatment segment is readjusted to a revised 5% CAGR for the next 8-year period.
The U.S. Market is Estimated at $1.8 Billion, While China is Forecast to Grow at 4.9% CAGR
The Chronic Myelogenous Leukemia Treatment market in the U.S. is estimated at US$1.8 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 4.9% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.1% and 4.3% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR.Select Competitors (Total 42 Featured) -
- Bio-Path Holdings, Inc.
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche AG
- Incyte Corporation
- Novartis AG
- Pfizer, Inc.
- Teva Pharmaceutical Industries Ltd.
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and the publisher's Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIV. COMPETITION
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Chronic Myelogenous Leukemia Treatment - Global Key Competitors Percentage Market Share in 2022 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
- Impact of Covid-19 and a Looming Global Recession
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 2: World Historic Review for Chronic Myelogenous Leukemia Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 3: World 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
- Table 4: World Recent Past, Current & Future Analysis for Disease Specific Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 5: World Historic Review for Disease Specific Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 6: World 16-Year Perspective for Disease Specific Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 7: World Recent Past, Current & Future Analysis for Symptomatic Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 8: World Historic Review for Symptomatic Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 9: World 16-Year Perspective for Symptomatic Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 10: World Recent Past, Current & Future Analysis for Branded by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 11: World Historic Review for Branded by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 12: World 16-Year Perspective for Branded by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 13: World Recent Past, Current & Future Analysis for Generic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 14: World Historic Review for Generic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 15: World 16-Year Perspective for Generic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 16: World Chronic Myelogenous Leukemia Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
III. MARKET ANALYSIS
- UNITED STATES
- Chronic Myelogenous Leukemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
- Table 17: USA Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 18: USA Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 19: USA 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2014, 2023 & 2030
- Table 20: USA Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 21: USA Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 22: USA 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2014, 2023 & 2030
- CANADA
- Table 23: Canada Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 24: Canada Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 25: Canada 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2014, 2023 & 2030
- Table 26: Canada Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 27: Canada Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 28: Canada 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2014, 2023 & 2030
- JAPAN
- Chronic Myelogenous Leukemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
- Table 29: Japan Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 30: Japan Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 31: Japan 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2014, 2023 & 2030
- Table 32: Japan Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 33: Japan Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 34: Japan 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2014, 2023 & 2030
- CHINA
- Chronic Myelogenous Leukemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
- Table 35: China Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 36: China Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 37: China 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2014, 2023 & 2030
- Table 38: China Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 39: China Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 40: China 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2014, 2023 & 2030
- EUROPE
- Chronic Myelogenous Leukemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
- Table 41: Europe Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 42: Europe Historic Review for Chronic Myelogenous Leukemia Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 43: Europe 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
- Table 44: Europe Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 45: Europe Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 46: Europe 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2014, 2023 & 2030
- Table 47: Europe Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 48: Europe Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 49: Europe 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2014, 2023 & 2030
- FRANCE
- Chronic Myelogenous Leukemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
- Table 50: France Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 51: France Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 52: France 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2014, 2023 & 2030
- Table 53: France Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 54: France Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 55: France 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2014, 2023 & 2030
- GERMANY
- Chronic Myelogenous Leukemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
- Table 56: Germany Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 57: Germany Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 58: Germany 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2014, 2023 & 2030
- Table 59: Germany Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 60: Germany Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 61: Germany 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2014, 2023 & 2030
- ITALY
- Table 62: Italy Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 63: Italy Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 64: Italy 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2014, 2023 & 2030
- Table 65: Italy Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 66: Italy Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 67: Italy 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2014, 2023 & 2030
- UNITED KINGDOM
- Chronic Myelogenous Leukemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
- Table 68: UK Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 69: UK Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 70: UK 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2014, 2023 & 2030
- Table 71: UK Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 72: UK Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 73: UK 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2014, 2023 & 2030
- REST OF EUROPE
- Table 74: Rest of Europe Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 75: Rest of Europe Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 76: Rest of Europe 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2014, 2023 & 2030
- Table 77: Rest of Europe Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 78: Rest of Europe Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 79: Rest of Europe 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2014, 2023 & 2030
- ASIA-PACIFIC
- Chronic Myelogenous Leukemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
- Table 80: Asia-Pacific Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 81: Asia-Pacific Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 82: Asia-Pacific 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2014, 2023 & 2030
- Table 83: Asia-Pacific Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 84: Asia-Pacific Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 85: Asia-Pacific 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2014, 2023 & 2030
- REST OF WORLD
- Table 86: Rest of World Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 87: Rest of World Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 88: Rest of World 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2014, 2023 & 2030
- Table 89: Rest of World Recent Past, Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 90: Rest of World Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 91: Rest of World 16-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2014, 2023 & 2030
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Bio-Path Holdings, Inc.
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche AG
- Incyte Corporation
- Novartis AG
- Pfizer, Inc.
- Teva Pharmaceutical Industries Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 194 |
| Published | April 2024 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 6 Billion |
| Forecasted Market Value ( USD | $ 9 Billion |
| Compound Annual Growth Rate | 5.2% |
| Regions Covered | Global |
